reaction volume of 10 L with 0.5 M each of the primers 5Ј-AGCACCAAGCAATATCATTTATG-3Ј and 5Ј-GC-CTCCAAGTATCTGCACAG-3Ј, 50 ng of genomic DNA, and 0.5 M each of the anchor and detection probes (TIB MOLBIOL). The anchor probe 5Ј-CCAAGCTGCTCTCTG-GTAACTCATT-3Ј was labeled at the 3Ј end with fluorescein; the sensor probe 5Ј-AGCTAGTTCAACTTTCATT-GCCAT-3Ј was labeled with LightCycler Red 640 at its 5Ј end and modified at its 3Ј end by phosphorylation to block extension. As reaction buffer in the PCR, the Light-Cycler DNA-Master hybridization Probes 10ϫ buffer (Roche Diagnostics) with a final MgCl 2 concentration of 3.5 mM was used. Cycling conditions were as follows: 95°C for 1 min; and 40 cycles of 95°C for 0 s, 59°C for 20 s, and 72°C for 20 s (ramping rate, 20°C/s). Fluorescence was monitored at the end of each 20-s annealing phase. After amplification, melting curves were generated by denaturation at 95°C for 0 s, holding the samples at 50°C for 20 s, and then heating the sample to 75°C at 0.2°C/s, simultaneously monitoring the decline in fluorescence. Melting curves were converted to melting peaks by calculating the negative derivative of the fluorescence with respect to temperature (-dF/dT) against temperature (T).
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The measurement of troponins in blood has rapidly become an alternative to conventional methods of detecting myocardial damage (1) (2) (3) (4) (5) (6) (7) (8) , particularly in unstable angina, and several studies have indicated the prognostic importance of increased troponins in various clinical settings (9 -14 ) . These studies, however, have also pointed out the need for more sensitive methods because patients with even small increases of troponin seem to be at increased risk of cardiac events. Currently, cardiac troponin I (cTnI) can be quantified by assays from several manufacturers (15) (16) (17) (18) (19) , whereas only one company currently commercializes a cardiac troponin T assay (2, 20, 21 ) . The aim of this work was to evaluate the analytical performance of a new generation of the Access cTnI assay. We also provide data on values in apparently healthy subjects.
Venous blood was drawn from 70 patients admitted to our Coronary Care Unit because of suspicion of an acute coronary syndrome. Only patients found to have increased myocardial markers such as creatine kinase-MB and troponin I were included. The study was approved by the ethics committee of the Medical Faculty of Uppsala University. Serum samples were also obtained from 122 apparently healthy subjects (70 women and 52 men; median age, 41 years; range, 26 -73 years) as part of a health-screening program.
The new ACCESS cTnI assay (Beckman Coulter, Inc., Curves 1, 2, and 3 represent wild-type, homozygous mutant, and heterozygous samples, respectively. Each analysis included a heterozygous DNA control and a water control, which was negative (data not shown).
Chaska, MN) is a two-site immunoenzymatic (sandwich) immunoassay. Paramagnetic particles coated with mouse monoclonal anti-cTnI, mouse monoclonal anti-cTnI-alkaline phosphatase conjugate, and sample are added to a reaction vessel to form a particle-cTnI-conjugate sandwich. The cTnI in the sample binds to the immobilized anti-cTnI on the solid phase. The mouse anti-cTnI conjugate reacts with a different antigenic site on the cTnI molecule. Separation in a magnetic field and washing remove materials not bound to the solid phase. A chemiluminescent substrate (dioxetane Lumigen PPD) is added to the reaction vessel, and light generated by the reaction is measured with a luminometer. The photon production is proportional to the quantity of cTnI in the sample. The amount of analyte is determined by means of a stored multipoint calibration curve.
We defined the detection limit as the concentration of cTnI at a signal 2 SD above the mean signal of 10 replicates of the zero calibrator, as calculated from the calibration curve. Three studies were performed on one lot of reagents. The mean detection limit was 0.0036 g/L (range, 0.0024 -0.005 g/L). The lower limit of the reporting range was defined as the concentration at which the variation in duplicate samples was Յ20% (CV) and was calculated by means of the computer software Multicalc ® (Wallac Oy). It was estimated by assaying serial dilutions of five different patient LiHeparin (cat. no. 367993; 3 mL PET tube; 72 IU of lithium heparinate; final concentration in filled tube, 48 IU/mL of blood; BD Vacutainer Systems) plasma samples with increased cTnI (range, 0.21-0.81 g/L). The lower limit was 0.0085 g/L. In the same experiment, the cTnI at a CV of 10% was 0.03 g/L.
To determine assay imprecision, in one set of experiments trilevel controls provided by Beckman Coulter (range, 0.582-29.2 g/L) were analyzed in triplicate in a total of 36 assays representing 6 tests per day during 6 different days. The model used to estimate imprecision was a one-way ANOVA, assuming random effect. Estimates were calculated for intraassay, interassay, and total imprecision for each control level and showed intraassay variations (CVs) of 2.2-3.2%, interassay variations of 1.2-4.4%, and total imprecision of 2.5-5.4%. In an additional study, three patient samples (LiHeparin) with mean cTnI values (range) of 0.098 g/L (0.09 -0.11g/L), 0.069 g/L (0.06 -0.07 g/L), and 0.034 g/L (0.03-0.04 g/L) were assayed six times on each of 2 separate days, and the total imprecision was calculated. The CVs were 6.4%, 4.3%, and 15%, respectively.
A linearity study was performed with LiHeparinplasma samples from six subjects with increased cTnI (0.86 -75 g/L). The samples were measured in quadruplicate at five different dilutions (0.8, 0.6, 0.4, 0.2, and 0.1). The mean apparent recovery was 98.5% (95% confidence interval, 95.9 -101.0%). To analyze the linearity at lower concentrations, we used the results for the estimation of the functional sensitivity as above. As shown in Fig. 1A , dilutions of the five patient samples were linear down to cTnI concentrations Ͻ0.03 g/L (r ϭ 0.9991).
In vitro sample stability was tested using matched serum and LiHeparin-plasma samples obtained from eight patients with cTnI concentrations ranging from 0.81 to 52.0 g/L. Accepting a Ϯ 10% deviation from the values at 0 h, cTnI was stable in LiHeparin-plasma samples left at room temperature for 48 h after blood sampling, although the values at 48 h showed increased variation (median, 91%; range, 85-111%). After Ն72 h at room temperature, mean results were 80% of the initial concentration. Values in LiHeparin-plasma samples stored at 4°C also changed Ͻ10% at 48 h, and median values were 89% of control (range, 85-98%) at 72 h or more. The in vitro stability of cTnI in serum was similar to that in LiHeparin plasma at both temperatures. In all sample types, the changes after storage at either room temperature or 4 o C were independent of the initial cTnI concentration. Five freeze-thaw cycles with four samples at different concentrations had no significant effect on cTnI recovery (median, 100%; range, 92-107%). A sample type comparison was performed in matched serum and LiHeparin-plasma samples (n ϭ 54) collected at the same time from the same subject (Fig. 1B) . Results in LiHeparin plasma and serum were not significantly different [2.4% lower in serum (95% confidence interval, Ϫ1.3% to 6.1%)]. Plasma and serum showed a correlation coefficient of 0.9975.
In 122 sera from apparently healthy subjects, the cTnI concentrations of all except 2 subjects were Ͻ0.01 g/L. Thus, the 95th and 99th percentiles were 0.01 and 0.02 g/L, respectively, in this group.
We conclude that the new generation of Access cTnI assay has several desirable features. The lower limit of the reported range is below the 95th percentile of our preliminary reference range for a healthy population. Both serum and LiHeparin plasma may be used for measurement of cTnI, although there was a tendency to lower values in LiHeparin plasma at lower cTnI concentrations.
[Part of this difference might be explained by the loss in cTnI that has been shown to occur for both cTnI and troponin T during the early phase of acute myocardial infarction (22, 23 ) . The data presented in this study, however, do not allow conclusions on this point.] When measured by this assay, cTnI is stable in vitro at both room temperature and 4°C and can be stored up to 48 h under these conditions without any major effect on recovery. It seems, however, reasonable to recommend storage for Ͻ24 h. [The in vitro stability observed with the new generation cTnI assay contrasts with our experience with the Access first-generation cTnI assay. Indeed, storage of samples at room temperature for 1-2 h produced decreases of 20 -30% of the measured cTnI concentration (unpublished observations and Ref. (15 ) .]
The improved in vitro stability may be explained by the selection of different monoclonal antibodies to develop the new generation cTnI assay. According to Beckman Coulter, Inc., the monoclonal antibodies used in the new generation cTnI assay were selected based on published information that suggested that the antibodies recognize epitopes located within a region encompassing amino acids 30 -110 in the N-terminal half of the cTnI molecule. In recent studies, the region encompassing amino acids 30 -110 was shown to be more resistant to proteolytic cleavage (15, 24 ) .
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